[go: up one dir, main page]

Moore et al., 2004 - Google Patents

Both the D-(+) and L-(−) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity

Moore et al., 2004

Document ID
13006609821200794479
Author
Moore S
Huckerby T
Gibson G
Fullwood N
Turnbull S
Tabner B
El-Agnaf O
Allsop D
Publication year
Publication venue
Biochemistry

External Links

Snippet

The underlying cause of Alzheimer's disease is thought to be the aggregation of monomeric β-amyloid (Aβ), through a series of toxic oligomers, which forms the mature amyloid fibrils that accumulate at the center of senile plaques. It has been reported that l-(−)-nicotine …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Similar Documents

Publication Publication Date Title
Moore et al. Both the D-(+) and L-(−) enantiomers of nicotine inhibit Aβ aggregation and cytotoxicity
Salomon et al. Nicotine inhibits amyloid formation by the β-peptide
Batkulwar et al. Advanced glycation end products modulate amyloidogenic APP processing and tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer’s disease
Gafson et al. Neurofilaments: neurobiological foundations for biomarker applications
Zou et al. Amyloid β‐protein (Aβ) 1–40 protects neurons from damage induced by Aβ1–42 in culture and in rat brain
Murray et al. Amyloid β protein: Aβ40 inhibits Aβ42 oligomerization
Soong et al. Association of highly compact type II diabetes related islet amyloid polypeptide intermediate species at physiological temperature revealed by diffusion NMR spectroscopy
Tõugu et al. Zn (II)‐and Cu (II)‐induced non‐fibrillar aggregates of amyloid‐β (1–42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators
Busciglio et al. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome
Jakubowski et al. Interactions between curcumin derivatives and amyloid-β fibrils: insights from molecular dynamics simulations
Hou et al. Sulforaphane inhibits the generation of amyloid-β oligomer and promotes spatial learning and memory in Alzheimer’s disease (PS1V97L) transgenic mice
Cummins et al. Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo?
Gorantla et al. Molecular cobalt (II) complexes for tau polymerization in Alzheimer’s disease
Rohn The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities
Belluti et al. Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010–2012)
Novick et al. Design of β-amyloid aggregation inhibitors from a predicted structural motif
Ma et al. Modulating conformation of Aβ-peptide: an effective way to prevent protein-misfolding disease
Beasley et al. Lipid membranes influence the ability of small molecules to inhibit huntingtin fibrillization
Malishev et al. Toxicity inhibitors protect lipid membranes from disruption by Aβ42
Maezawa et al. Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment‐associated cytotoxicity
Sanders et al. Structural and mechanistic insights into amyloid‐β and α‐synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers
Townsend et al. Epigallocatechin-3-gallate remodels apolipoprotein AI amyloid fibrils into soluble oligomers in the presence of heparin
Singh et al. Binding of noradrenaline to native and intermediate states during the fibrillation of α-synuclein leads to the formation of stable and structured cytotoxic species
de Almeida et al. Opposing Effects of Cucurbit [7] uril and 1, 2, 3, 4, 6-Penta-O-galloyl-β-d-glucopyranose on Amyloid β25–35 Assembly
Fuentealba et al. Synaptic failure and adenosine triphosphate imbalance induced by amyloid‐β aggregates are prevented by blueberry‐enriched polyphenols extract